These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 31391211)

  • 1. Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence.
    Dunn KE; Huhn AS; Bergeria CL; Gipson CD; Weerts EM
    J Pharmacol Exp Ther; 2019 Nov; 371(2):422-452. PubMed ID: 31391211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medications Development for Treatment of Opioid Use Disorder.
    Townsend EA; Negus SS; Banks ML
    Cold Spring Harb Perspect Med; 2021 Jan; 11(1):. PubMed ID: 31932466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medications development for opioid abuse.
    Negus SS; Banks ML
    Cold Spring Harb Perspect Med; 2013 Jan; 3(1):a012104. PubMed ID: 23125072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management.
    Pergolizzi JV; Raffa RB; Rosenblatt MH
    J Clin Pharm Ther; 2020 Oct; 45(5):892-903. PubMed ID: 31986228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive Management of Opioid Withdrawal with the Nonopioid Medication Cannabidiol.
    Kudrich C; Hurd YL; Salsitz E; Wang AL
    Cannabis Cannabinoid Res; 2022 Oct; 7(5):569-581. PubMed ID: 34678050
    [No Abstract]   [Full Text] [Related]  

  • 7. Addiction: the clinical interface.
    Nutt D; Lingford-Hughes A
    Br J Pharmacol; 2008 May; 154(2):397-405. PubMed ID: 18414399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report.
    Szczesniak LM; Calleo VJ; Sullivan RW
    Harm Reduct J; 2020 Oct; 17(1):71. PubMed ID: 33028340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fentanyl withdrawal: Understanding symptom severity and exploring the role of body mass index on withdrawal symptoms and clearance.
    Luba R; Jones J; Choi CJ; Comer S
    Addiction; 2023 Apr; 118(4):719-726. PubMed ID: 36444486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine.
    Jordan CJ; Cao J; Newman AH; Xi ZX
    Neuropharmacology; 2019 Nov; 158():107609. PubMed ID: 31009632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjunctive memantine for opioid use disorder treatment: A systematic review.
    Elias AM; Pepin MJ; Brown JN
    J Subst Abuse Treat; 2019 Dec; 107():38-43. PubMed ID: 31757263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishing a research agenda for the study and assessment of opioid withdrawal.
    Dunn KE; Strain EC
    Lancet Psychiatry; 2024 Jul; 11(7):566-572. PubMed ID: 38521089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
    Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combating opiate dependence: a comparison among the available pharmacological options.
    Gonzalez G; Oliveto A; Kosten TR
    Expert Opin Pharmacother; 2004 Apr; 5(4):713-25. PubMed ID: 15102558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suspected Buprenorphine-Precipitated Opioid Withdrawal following Intercourse: A Case Report.
    Lynch D; Chitty L; Johnson B; Hoefnagel AL
    J Pain Palliat Care Pharmacother; 2023 Dec; 37(4):314-316. PubMed ID: 37640398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
    Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL
    Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approach to buprenorphine use for opioid withdrawal treatment in the emergency setting.
    Cisewski DH; Santos C; Koyfman A; Long B
    Am J Emerg Med; 2019 Jan; 37(1):143-150. PubMed ID: 30355476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose buprenorphine for treatment of high potency opioid use disorder.
    Danilewitz M; McLean M
    Drug Alcohol Rev; 2020 Feb; 39(2):135-137. PubMed ID: 31769109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD?
    Dong KA; Duthie KM
    AMA J Ethics; 2024 Jul; 26(7):E512-519. PubMed ID: 38958419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.